Zobrazeno 1 - 10
of 81
pro vyhledávání: '"David G. Tubergen"'
Publikováno v:
Journal of Pediatric Hematology/Oncology. 21:63-66
Purpose: Transient leukemia and extreme basophilia occurred in a phenotypically normal newborn with expression of isochromosome (21)(q10) in the blast population. Patients and Methods: A newborn boy was found to have an elevated white blood cell coun
Autor:
John S. Holcenberg, W. Archie Bleyer, Matthew M. Ames, Jeffrey Ge, Solomon Zimm, Robert F. Murphy, Mary J. Waskerwitz, Gerald S. Gilchrist, David G. Tubergen, David G. Poplack, Frank M. Balis, Harland N. Sather
Publikováno v:
Blood. 92:3569-3577
We prospectively assessed the pharmacokinetics of methotrexate, mercaptopurine, and erythrocyte thioguanine nucleotide levels in a homogenous population of children with lower risk acute lymphoblastic leukemia and correlated pharmacokinetic parameter
Autor:
Paul S. Gaynon, Roger P. Qu, Michael L. N. Willoughby, Peter G. Steinherz, David G. Tubergen, Rick Chappell, Michael E. Trigg
Publikováno v:
Cancer. 82:1387-1395
BACKGROUND Childhood acute lymphoblastic leukemia is the single most common childhood malignancy. Despite substantial improvements in therapy, cases in which relapse occurs are still more common than newly diagnosed cases of many other childhood canc
Autor:
Gregory H. Reaman, Beverly J. Lange, Harland N. Sather, Raymond J. Hutchinson, Peter G. Steinherz, Paul S. Gaynon, James B. Nachman, Michael E. Trigg, Anish A. Desai, Bruce C. Bostrom, David G. Tubergen, Fatih M. Uckun
Publikováno v:
Cancer. 80:1717-1726
BACKGROUND Early response to therapy is defined as the initial response prior to Day 28 of treatment, the conventional time of marrow evaluation. The number of reports linking early response to therapy with the ultimate outcome of childhood acute lym
Autor:
Zhiwen Yang, James B. Nachman, Lisa Crotty, Fatih M. Uckun, Tamer Zeren, Gregory H. Reaman, Mireille Sarquis, Paul S. Gaynon, Bruce Bostrom, Harland N. Sather, David G. Tubergen, Peter G. Steinherz, Onur Ek
Publikováno v:
Blood. 89:3769-3777
We found a marked variation in BCL-2 oncoprotein expression levels of primary leukemic cells from 338 children with newly diagnosed acute lymphoblastic leukemia (ALL). None of the high-risk features predictive of poor treatment outcome in childhood A
Autor:
Gerald B. Sharp, Carol A. Greenwald, Sue C. Kaste, Deborah B. Crom, Melissa M. Hudson, David G. Tubergen
Publikováno v:
Medical and Pediatric Oncology. 28:15-21
We prospectively used ultrasonography to detect thyroid abnormalities in 96 long-term survivors of childhood cancer, who received head and neck radiation therapy at a median age of 8.9 years. The median time interval since irradiation was 10.8 years
Publikováno v:
Journal of Pediatric Hematology/Oncology. 18:106-112
The frequency and cost of varicella and varicella exposure were determined in children receiving maintenance chemotherapy for acute lymphocytic leukemia, and the cost of a preventative strategy using the varicella vaccine was estimated.Retrospective
Autor:
Diane C. Arthur, David G. Tubergen, G Reamon, Michael P. Link, Stephen E. Sallan, Harland N. Sather, Jonathan J. Shuster, Bruce M. Camitta, Andrew J. Carroll, Richard M. Simon, Fatih M. Uckun, Richard D. Gelber, Nyla A. Heerema, Sharon E. Murphy, C H Pui, Paul S. Gaynon, Michael E. Trigg, Richard S. Ungerleider, Edward L. Korn, M Smith, J Pullen, W M Crist
Publikováno v:
Journal of Clinical Oncology. 14:18-24
PURPOSE To define more uniform criteria for risk-based treatment assignment for children with acute lymphoblastic leukemia (ALL), the Cancer Therapy Evaluation Program (CTEP) of the National Cancer Institute (NCI) sponsored a workshop in September 19
Autor:
David G. Tubergen, Fatih M. Uckun, G Reaman, Harland Sather, Peter G. Steinherz, Diane C. Arthur, Michael E. Trigg, Paul S. Gaynon
Publikováno v:
Leukemia & Lymphoma. 24:57-70
The prognostic importance of T-lineage acute lymphoblastic leukemia (ALL) in contemporary programs of intensive chemotherapy has been controversial. We therefore assessed the impact of this biological feature in risk-adjusted frontline chemotherapy s
Autor:
John H. Kersey, Jeffrey G. Rosenstock, Marshall E. Kadin, Mark Krailo, Peter G. Steinherz, Denis R. King, David G. Tubergen, Anna T. Meadows, Margaret Morse
Publikováno v:
Journal of Clinical Oncology. 13:1368-1376
PURPOSE Patients with lymphoblastic non-Hodgkin's lymphoma (LB NHL) were randomized to treatment with either modified LSA2L2 or ADCOMP, which added daunorubicin (DAUN) and asparaginase (L-ASP) to the methotrexate (MTX), cyclophosphamide (CYT), vincri